Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN FRANCISCO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients with...
-
SAN FRANCISCO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug...
-
New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndromes (MDS) regardless of ring sideroblast (RS) or baseline erythropoietin level ...
-
SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D.,...
-
SAN FRANCISCO and TOKYO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,...
-
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
-
- Strong Third Quarter China Roxadustat Net Sales of $22.7 Million -- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN FRANCISCO, Nov. 05, 2020 (GLOBE NEWSWIRE) --...
-
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen will...
-
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 10 g/dL Two analyses of...
-
Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease (CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk...